Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

Lipshultz, Steven E.; Scully, Rebecca E.; Lipsitz, Stuart R.; Sallan, Stephen E.; Silverman, Lewis B.; Miller, Tracie L.; Barry, Elly; Asselin, Barbara L.; Athale, Uma H.; Clavell, Luis A.; Larsen, Eric; Moghrabi, Albert; Samson, Yvan; Michon, Bruno; Schorin, Marshall A.; Cohen, Harvey J.; Neuberg, Donna; Orav, E. John; Colan, Steven D.

doi:10.1016/s1470-2045(10)70204-7

Cited by 386 publications

(328 citation statements)

References 83 publications

Supporting

Mentioning

302

Contrasting

Unclassified

Order By: Relevance

“…We investigated the effects of anti-ischemia drugs, losartan and diltiazem, as well as dexrazoxane, which have been shown to provide long-term cytoprotection without affecting the efficacy of doxorubicin (28). Dose response experiments for cytoprotective effect were performed using rat myoblast (H9c2) cells in the presence of doxorubicin and irinotecan, and the listed cytoprotective and anti-ischemia drugs.…”

Section: Discussionmentioning

confidence: 99%

Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line

et al. 2013

View full text Add to dashboard Cite

To investigate potential prevention or attenuation of anti- cancer drug induced cardiotoxicity using anti-ischemic drugs, a rat myoblast (H9c2) cell line was used as our in vitro cardiac model. Irinotecan and doxorubicin were found to be cytotoxic for the H9c2 cell line with IC50 of 30.69 ± 6.20 and 20.94 ± 6.05 mmol L-1, respectively. 5-Flurouracil and cladribine were not cytotoxic and thus IC50 could not be calculated. When 100 mmol L-1 doxorubicin was incubated for 72 hours with 50 mmol L-1 diltiazem, 100 mmol L-1 dexrazoxane and 100 mmol L-1 losartan, respectively, there was a 58.7 ± 10.2, 52.2 ± 11.7 and 44.7 ± 5.4 % reduction in cell death. When 200 mmol L-1 irinotecan was incubated for 72 hours with 100 mmol L-1 dexrazoxane, losartan and diltiazem, respectively, a 27.7 ± 6.9, 25.6 ± 5.1, and 19.1 ± 2.3 % reduction in cell death was observed. Our data suggests that losartan and diltiazem were as effective as dexrazoxane in protecting the cells against irinotecan- and doxorubicin-induced cell toxicity. These findings offer potential uses of anti- -ischemic drugs for ablation of cytotoxicity in response to mitochondrial injury, thereby improving patient outcomes and reducing health-care costs.

show abstract

Section: Discussionmentioning

confidence: 99%

Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line

et al. 2013

View full text Add to dashboard Cite

show abstract

“…(15) Further studies have demonstrated that TnI is also a sensitive and specific marker for myocardial injury in adults treated with high-dose chemotherapy (CT), and is able to predict, at a very early phase, both development and severity of future LVD ( Figure 1). (16)(17)(18) Additionally, in 703 Patients showing an increase of TnI during trastuzumab treatment had a three-fold lower chance of recovery from cardiac dysfunction and had a higher incidence of cardiac events ( showing only a transient increase in this marker.…”

Section: Troponinsmentioning

confidence: 99%

Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy

Bacchiani

Cardinale

2017

SAHJ

View full text Add to dashboard Cite

Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy goal for both cardiologists and oncologists. The main strategy to prevent clinical cardiotoxicity is early detection and the initiation of prompt prophylactic therapy. EARLY DETECTION OF CARDIOTOXICITY Current approachPeriodic assessment for LVEF is the most widely used non-invasive method for detecting cardiotoxicity LVEF either via echocardiography or multigated acquisition scanning. Although several available guidelines exist none specify how often, by what means or how long cardiac function should be monitored during and after cancer treatment. The recommendations of these guidelines are not consistent and seem to be based on modest evidence. Though LVEF is a crude index of cardiac function, it is relatively insensitive in detecting anticancer drug-induced cardiotoxicity at an early stage. Usually there are compensatory mechanisms in place to ensure normal overall function in a patient despite an initial reduction in myocardial contractility. As a rule no considerable

show abstract

“…Currently, dexrazoxane is the only cardioprotective drug used in clinical practice with a proven effi cacy in reducing side effects of anthracycline-based chemotherapy in cancer patients by reduction of the incidence and severity of anthracycline-induced congestive heart failure and adverse cardiac events (Lipshultz et al 2010 ;Lyu et al 2007 ).…”

Section: Treatment Of Chemotherapeuticinduced Cardiotoxicitymentioning

confidence: 99%

Female Pelvis: Genital Organs

Forstner

Cunha²

2015

Imaging of Complications and Toxicity Following Tumor Therapy

View full text Add to dashboard Cite

Medical Radiology-Diagnostic Imaging is a unique series that aims to document the most innovative technologies in all fi elds within diagnostic imaging and interventional radiology, thereby informing the physician in practice of the latest advances in diagnostic imaging and percutaneous imageguided minimally invasive procedures. Th e contents are intended to cover all organs, and all modern imaging techniques and image-guided treatment modalities, with special emphasis on applications in clinical practice. Each volume is a comprehensive reference book on a topical theme, and the editors are always experts of high international standing. Contributions are included from both clinicians and researchers, ensuring wide appeal. Medical Radiology -Radiation Oncology is a unique series that aims to document the most innovative technologies in all fi elds within radiology, thereby informing the physician in practice of the latest advances in diagnostic and treatment techniques. Th e contents range from contemporary statements relating to management for various disease sites to explanations of the newest techniques for tumor identifi cation and of mechanisms for the enhancement of radiation eff ects, with the emphasis on maximizing cure and minimizing complications. Each volume is a comprehensive reference book on a topical theme, and the editors are always experts of high international standing. Contributions are included from both clinicians and researchers, ensuring wide appeal. This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specifi c statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. AbstractA precise knowledge of antineoplastic drugs is an indispensable basis for the care of patients with cancer. The mechanisms of action and resistance, cross-resistance patterns, pharmacodynamics and pharmacokinetics, pharmacological interaction, and last but not least potential adverse effects should be part of this knowledge. As contemporary cancer care requires interdisciplinary and multiprofessional structures, the radiologist is an important a...

show abstract

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

Cited by 386 publications

References 83 publications

Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line

Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line

Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy

Female Pelvis: Genital Organs

Contact Info

Product

Resources

About